Renin-Angiotensin System

A renin-angiotensin system combination polypill to treat high BP was associated with improved adherence and lower all-cause mortality and CV event rates vs. taking multiple pills, researchers reported.

Among patients who underwent transcatheter aortic valve replacement, those who filled prescriptions for statins and ACE inhibitors or angiotensin receptor blockers had lower mortality risk at 3 years vs. those who did not, data show.

The benefits of HF medications are additive and incremental and provide similar benefits to patients with ischemic and nonischemic etiologies when initiated simultaneously, according to a speaker.

The detection, recognition, monitoring, referrals and management of chronic kidney disease significantly differs between men and women, according to data published in Journal of the American Society of Nephrology.

Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was associated with lower risk for aneurysm rupture compared with nonuse, according to research published in Hypertension.

A retracted New England Journal of Medicine study on the link between CVD, renin-angiotensin–aldosterone system inhibitor therapy and COVID-19 outcomes continues to be “widely cited” in medical literature, researchers wrote.

Stopping vs. continuing ACE inhibitors and angiotensin receptor blockers in patients hospitalized for COVID-19.

Dual vaping and traditional cigarette use induced responses that are similar to stresses caused by traditional cigarette use, nationally representative data showed. It was the top story in cardiology last week.

It is safe for patients hospitalized with COVID-19 to continue using renin-angiotensin system inhibitors, researchers reported.

Researchers from the Netherlands have identified benefits and risks associated with stopping renin-angiotensin system inhibitor therapy in patients with advanced chronic kidney disease.